Publication | Open Access
<i>In Vitro</i> Susceptibility of Mycobacterium tuberculosis Isolates to an Oral Carbapenem Alone or in Combination with β-Lactamase Inhibitors
44
Citations
25
References
2014
Year
Mycobacterium Tuberculosis IsolatesTuberculosis PreventionAntimicrobial ChemotherapyOral Carbapenem AloneDrug ResistanceMycobacterium TuberculosisAntimicrobial TherapyAntimicrobial ResistanceHealth SciencesPulmonary TuberculosisAntimicrobial Drug DiscoveryDrug Resistance Analysisβ-Lactamase InhibitorsTuberculosisMic RangeAntibacterial AgentAntimicrobial PharmacokineticsPharmacologyClinical MicrobiologyOral CarbapenemAntimicrobial SusceptibilityAntibioticsCombination TherapyMicrobiologyAntimicrobial PharmacodynamicsMedicineDrug Discovery
We evaluated the antituberculosis (anti-TB) activity of five β-lactams alone or in combination with β-lactamase inhibitors against 41 clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains. Of those, tebipenem, an oral carbapenem, showed the most potent anti-TB activity against clinical isolates, with a MIC range of 0.125 to 8 μg/ml, which is achievable in the human blood. More importantly, in the presence of clavulanate, MIC values of tebipenem declined to 2 μg/ml or less.
| Year | Citations | |
|---|---|---|
Page 1
Page 1